Glycomine

Developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist.

Launch date

2013

Employees

Market cap

Enterprise valuation

San Carlos California (HQ)

Date	Investors	Amount	Round
-	MBC Biolabs For Good Ventures	N/A	-
Nov 2016	Chiesi Ventures Sanderling Ventures	$12.0m	Series A
Aug 2019*	Novo Holdings Novo Seeds	$33.0m	Series B
Jun 2021	Abingworth RiverVest Venture Partners Novo Holdings Chiesi Ventures Remiges Ventures Sanderling Ventures Sanofi Ventures Mission BioCapital Asahi Kasei Pharma	$35.0m	Series B
Total Funding		CAD109m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Glycomine